A phase II study of gefitinib in PS3 (4) advanced adenocarcinoma of the lung
Not Applicable
- Conditions
- PS 3 patients (or PS 4 patients because of bone or brain metastasis) with advanced adenocarcinoma of the lung.
- Registration Number
- JPRN-C000000187
- Lead Sponsor
- Department of Medical Oncology, Kinki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with apparent abnormalities on chest X-ray, acute inflammation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, uncontrollable diabetes mellitus, severe infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate
- Secondary Outcome Measures
Name Time Method